T1	Qualifier 4 13	bilateral
T2	Condition 14 26	sacroiliitis
T3	Qualifier 27 34	Grade 2
T4	Qualifier 38 48	unilateral
T5	Condition 49 61	sacroiliitis
T6	Qualifier 62 69	Grade 3
T7	Qualifier 73 80	Grade 4
*	OR T6 T7
T8	Scope 62 80	Grade 3 or Grade 4
R1	Has_scope Arg1:T5 Arg2:T8	
R2	Has_qualifier Arg1:T5 Arg2:T4	
R3	Has_qualifier Arg1:T2 Arg2:T3	
*	OR T2 T5
R4	Has_qualifier Arg1:T2 Arg2:T1	
T9	Condition 87 94	nursing
T10	Condition 98 106	pregnant
T11	Person 107 113	female
*	OR T10 T9
T12	Condition 136 144	pregnant
T13	Temporal 145 193	within 6 months after receiving trial medication
R5	Has_temporal Arg1:T12 Arg2:T13	
T14	Mood 118 135	intends to become
R6	Has_mood Arg1:T12 Arg2:T14	
T15	Procedure 206 217	donate eggs
T16	Procedure 206 212;243 248	donate sperm
T17	Person 219 225	female
T18	Person 250 254	male
T19	Temporal 269 301	while receiving trial medication
T20	Temporal 305 343	within 6 months after trial medication
T21	Reference_point 327 343	trial medication
T22	Reference_point 285 301	trial medication
R7	Has_index Arg1:T19 Arg2:T22	
R8	Has_index Arg1:T20 Arg2:T21	
*	OR T19 T20
A1	Optional T17
A2	Optional T18
R9	AND Arg1:T17 Arg2:T15	
R10	AND Arg1:T18 Arg2:T16	
*	OR T17 T18
T23	Scope 206 268	donate eggs (female participants) or sperm (male participants)
T24	Scope 269 343	while receiving trial medication or within 6 months after trial medication
R11	Has_scope Arg1:T23 Arg2:T24	
T25	Post-eligibility 345 476	Has any clinically significant condition or situation that would interfere with the trial evaluations or participation in the trial
T26	Drug 500 515	cytotoxic drugs
T27	Drug 527 539	chlorambucil
T28	Drug 541 557	cyclophosphamide
T29	Drug 559 575	nitrogen mustard
T30	Drug 586 603	alkylating agents
*	OR T29 T30 T28 T27
T31	Scope 527 603	chlorambucil, cyclophosphamide, nitrogen mustard, or other alkylating agents
R12	Subsumes Arg1:T26 Arg2:T31	
T32	Drug 607 645	Disease-modifying anti-rheumatic drugs
T33	Temporal 647 663	30 days off drug
R13	Has_temporal Arg1:T32 Arg2:T33	
T34	Drug 668 685	Live vaccinations
T35	Temporal 687 704	3 months off drug
R14	Has_temporal Arg1:T34 Arg2:T35	
T36	Drug 709 736	Investigational medications
T37	Temporal 738 745;762 770	30 days off drug
T38	Temporal 749 770	5 half-lives off drug
*	OR T38 T37
T39	Scope 738 770	30 days or 5 half-lives off drug
R15	Has_scope Arg1:T36 Arg2:T39	
T40	Drug 796 837	Bacille Calmette-Guerin (BCG) vaccination
T41	Temporal 839 857	12 months off drug
R16	Has_temporal Arg1:T40 Arg2:T41	
T42	Condition 877 899	inflammatory condition
T43	Condition 911 930	psoriatic arthritis
T44	Condition 939 951	Lyme disease
T45	Qualifier 932 938	active
R17	Has_qualifier Arg1:T44 Arg2:T45	
T46	Condition 953 981	systemic lupus erythematosus
T47	Condition 983 1003	infectious arthritis
T48	Condition 1005 1015	vasculitis
T49	Condition 1017 1037	parvovirus infection
T50	Condition 1039 1059	rheumatoid arthritis
T51	Condition 1061 1075	active uveitis
T52	Condition 1080 1090	active IBD
*	OR T51 T52 T50 T49 T48 T47 T46 T44 T43
T53	Scope 911 1090	psoriatic arthritis, active Lyme disease, systemic lupus erythematosus, infectious arthritis, vasculitis, parvovirus infection, rheumatoid arthritis, active uveitis, or active IBD
R18	Subsumes Arg1:T42 Arg2:T53	
T54	Qualifier 1119 1125	active
T55	Qualifier 1109 1115	latent
*	OR T55 T54
T56	Condition 1126 1149	granulomatous infection
T57	Temporal 1150 1168	prior to Screening
T58	Reference_point 1159 1168	Screening
R19	Has_index Arg1:T57 Arg2:T58	
T59	Scope 1109 1125	latent or active
R20	Has_scope Arg1:T56 Arg2:T59	
R21	Has_temporal Arg1:T56 Arg2:T57	
T60	Condition 1176 1214	nontuberculous mycobacterial infection
T61	Condition 1218 1241	opportunistic infection
T62	Temporal 1242 1276	within 6 months prior to Screening
*	OR T61 T60
T63	Scope 1176 1241	nontuberculous mycobacterial infection or opportunistic infection
R22	Has_temporal Arg1:T63 Arg2:T62	
T64	Condition 1298 1306	infected
T65	Device 1307 1323	joint prosthesis
R23	AND Arg1:T64 Arg2:T65	
T66	Observation 1284 1291	history
R24	Has_temporal Arg1:T64 Arg2:T66	
T67	Drug 1341 1352	antibiotics
T68	Mood 1359 1368	suspected
T69	Condition 1369 1378	infection
T70	Device 1384 1400	joint prosthesis
R25	AND Arg1:T69 Arg2:T70	
R26	Has_mood Arg1:T69 Arg2:T68	
R27	AND Arg1:T67 Arg2:T69	
*	OR T64 T69
T71	Condition 1461 1478	serious infection
T72	Procedure 1489 1501	hospitalized
T73	Condition 1509 1518	infection
R28	AND Arg1:T72 Arg2:T73	
T74	Drug 1545 1559	IV antibiotics
T75	Condition 1567 1576	infection
T76	Temporal 1577 1610	within 2 months prior to Baseline
R29	Has_temporal Arg1:T74 Arg2:T76	
R30	AND Arg1:T74 Arg2:T75	
*	OR T72 T74 T71
T77	Qualifier 1653 1662	recurrent
T78	Qualifier 1642 1649	chronic
T79	Temporal 1633 1640	ongoing
T80	Observation 1618 1625	history
*	OR T77 T78
*	OR T79 T80
T81	Scope 1618 1640	history of, or ongoing
T82	Scope 1642 1662	chronic or recurrent
T83	Condition 1663 1681	infectious disease
R31	Has_scope Arg1:T83 Arg2:T82	
R32	Has_scope Arg1:T83 Arg2:T81	
T84	Condition 1712 1746	human immunodeficiency virus (HIV)
T85	Condition 1750 1790	seropositive for hepatitis C virus (HCV)
*	OR T84 T85
T86	Procedure 1802 1813	chest x-ray
T87	Temporal 1814 1848	within 2 months prior to Screening
T88	Condition 1863 1874	abnormality
T89	Mood 1875 1885	suggestive
T90	Temporal 1891 1898	current
T91	Qualifier 1899 1905	active
T92	Condition 1906 1915	infection
T93	Condition 1919 1929	malignancy
*	OR T92 T93
T94	Scope 1906 1929	infection or malignancy
R33	Has_qualifier Arg1:T94 Arg2:T91	
R34	Has_temporal Arg1:T94 Arg2:T90	
R35	Has_mood Arg1:T94 Arg2:T89	
R36	Has_scope Arg1:T88 Arg2:T94	
R37	Has_temporal Arg1:T86 Arg2:T87	
R38	AND Arg1:T86 Arg2:T88	
T95	Condition 1948 1975	lymphoproliferative disease
T96	Condition 1987 1997	malignancy
T97	Temporal 1998 2029	within 5 years before screening
R39	Has_temporal Arg1:T96 Arg2:T97	
T98	Reference_point 2020 2029	screening
R40	Has_index Arg1:T97 Arg2:T98	
T99	Reference_point 1839 1848	Screening
R41	Has_index Arg1:T87 Arg2:T99	
T100	Condition 2046 2054;2070 2092	squamous carcinomas of the skin
T101	Condition 2059 2092	basal cell carcinomas of the skin
*	OR T100 T101 T102
T102	Condition 2097 2114	carcinoma in situ
T103	Qualifier 2118 2124	cervix
R42	Has_qualifier Arg1:T102 Arg2:T103	
T104	Qualifier 2139 2155	surgically cured
T105	Procedure 2139 2149	surgically
R43	multi Arg1:T104 Arg2:T105	
R44	Has_qualifier Arg1:T102 Arg2:T104	
T106	Negation 2031 2041	exceptions
T107	Scope 2046 2155	squamous and basal cell carcinomas of the skin and carcinoma in situ of cervix that has been surgically cured
R45	Has_negation Arg1:T107 Arg2:T106	
R46	Has_scope Arg1:T96 Arg2:T107	
T108	Condition 2181 2203	demyelinating diseases
T109	Observation 2164 2171	history
R47	Has_temporal Arg1:T108 Arg2:T109	
T110	Condition 2212 2230	multiple sclerosis
T111	Condition 2234 2248	optic neuritis
*	OR T110 T111
T112	Scope 2212 2248	multiple sclerosis or optic neuritis
R48	Subsumes Arg1:T108 Arg2:T112	
T113	Condition 2281 2305	congestive heart failure
T114	Temporal 2270 2280	concurrent
T115	Observation 2256 2263	history
*	OR T114 T115
T116	Scope 2256 2280	history of or concurrent
R49	Has_scope Arg1:T113 Arg2:T116	
T117	Procedure 2326 2344	transplanted organ
T118	Procedure 2370 2388	corneal transplant
T119	Temporal 2399 2428	>= 3 months prior to baseline
R50	Has_temporal Arg1:T118 Arg2:T119	
T120	Negation 2355 2367	exception of
R51	Has_negation Arg1:T118 Arg2:T120	
R52	AND Arg1:T117 Arg2:T118	
T121	Condition 2476 2491	medical illness
T122	Qualifier 2464 2475	significant
R53	Has_qualifier Arg1:T121 Arg2:T122	
T123	Observation 2504 2528	interfere with the trial
T124	Mood 2533 2540	require
T125	Procedure 2541 2550	treatment
T126	Observation 2562 2586	interfere with the trial
R54	Has_mood Arg1:T125 Arg2:T124	
R55	Has_context Arg1:T125 Arg2:T126	
*	OR T123 T125
T127	Scope 2504 2586	interfere with the trial, or require treatment that might interfere with the trial
R56	Has_scope Arg1:T121 Arg2:T127	
T128	Intoxication_considerations 2588 2716	Is a user of recreational or illicit drugs or has or had a substance abuse (drug or alcohol) problem within the previous 2 years
